Our Science
Our Science
Cutting-edge research and technology
Our initiatives
Our initiatives
Campaigning for a smoke-free future
Smoke-Free Life
Smoke-Free Life
Go beyond your past, make a positive change
pmi-emblem

Why Invest in PMI?

We've built the worlds most succesful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 8850

-0.36 (-0.41%)

Investor Relations

Latest Press Releases

Media Center
  • News 13 Feb, 2020

    The greatest gift for Valentine’s Day: Why I quit smoking for my partner

  • Press Release 12 Feb, 2020

    Philip Morris International Inc. to Webcast Presentation at Consumer Analyst Group of New York (CAGNY) Conference

  • News 11 Feb, 2020

    International Day of Women and Girls in Science: Why we must strive for a better balance

  • News 11 Feb, 2020

    Women in science and tech are key to a better future

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOSin the U.S. as a modified risk product are currently under review.